ReviewCancer journal (Sudbury, Mass.)
BRCA mutation testing in determining breast cancer therapy.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Decoding the Genetic Hallmarks of Breast Cancer: Molecular Signatures, Prognostic and Therapeutic Perspectives.Applied biochemistry and biotechnology · 2026Review
- Preoperative Germline Genetic Testing and Surgical Timing in Breast Cancer: Implementation of National Reimbursement Programs: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- A predictive model using MRI and clinicopathologic features for breast cancer recurrence in young women treated with upfront surgery.European radiology · 2024Article
- Genetic Testing Among Breast Cancer Patients in the Eastern Region of Saudi Arabia: Single-Center Experience.Journal of epidemiology and global health · 2024Article
- BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork.Current oncology (Toronto, Ont.) · 2024Article
- Therapeutic Peptide RF16 Derived from CXCL8 Inhibits MDA-MB-231 Cell Invasion and Metastasis.International journal of molecular sciences · 2023Article
- Rare penetrant mutations confer severe risk of common diseases.medRxiv : the preprint server for health sciences · 2023Article
- Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study.Cancer medicine · 2021Article
- Germline BRCA Mutation and Clinical Outcomes in Breast Cancer Patients Focusing on Survival and Failure Patterns: A Long-Term Follow-Up Study of Koreans.Medicina (Kaunas, Lithuania) · 2020Article
- Rapid Microwave-Assisted Cisplatin-Loaded Solid Lipid Nanoparticles: Synthesis, Characterization and Anticancer Study.Nanomaterials (Basel, Switzerland) · 2020Article
- Mutational analysis of BRCA1 and BRCA2 in northwest Chinese breast cancer patients.Translational cancer research · 2019Article
- Article
- Review
- Surgery forEcancermedicalscience · 2018Review
- Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germlineCold Spring Harbor molecular case studies · 2017Article
- The Role of Knowledge on Genetic Counseling and Testing in Black Cancer Survivors at Increased Risk of Carrying a BRCA1/2 Mutation.Journal of genetic counseling · 2017Article
- An ovarian mass after breast cancer: Metachronous carcinoma or metastasis? A case report.International journal of surgery case reports · 2017Article
- Finding all BRCA pathogenic mutation carriers: best practice models.European journal of human genetics : EJHG · 2016Review
- Genomic rearrangement screening of theJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2016Article
- Legislation in the genomic era: the Affordable Care Act and genetic testing for cancer risk assessment.Genetics in medicine : official journal of the American College of Medical Genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
BRCA mutation-associated breast cancer differs from sporadic breast cancer with regard to future cancer risks and sensitivity to systemic therapies. Now that rapid genetic testing for BRCA1 and BRCA2 mutations is available at the time of breast cancer diagnosis, BRCA mutation status can be considered when making treatment and prevention decisions for BRCA mutation carriers with breast cancer. This article reviews surgical options for management of affected BRCA mutation carriers with emphasis on the risks of ipsilateral recurrence and contralateral breast cancer. The roles of breast-conserving surgery, prophylactic mastectomy, and oophorectomy are reviewed. In addition, the sensitivity of BRCA mutation-associated breast cancer to endocrine therapy, platinum chemotherapy, and poly (ADP-ribose) polymerase inhibitors is reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.